![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.25 | 1.59% | 16.00 | 15.50 | 16.50 | 16.00 | 15.75 | 15.75 | 133,591 | 08:09:01 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 5.55 | 14.36M |
Date | Subject | Author | Discuss |
---|---|---|---|
27/10/2016 15:00 | Yes. Thanks again... | ![]() bobdown2 | |
27/10/2016 14:59 | Cheers adnanwolf. Good to hear from someone who knows what they're talking about here. | ![]() someuwin | |
27/10/2016 14:57 | Sorry Kipper - that's wrong. Finncap were brought in because they specialise in biotchs and they are more suited to OPTI needs for the demerger. Finncap will also have a much larger clientele for potential new PI's. Patience need here. Listed 2 years ago, now profitable division (to be confirmed) as far as we can conclude from yesterday email. I for one believe someuwin email to be genuine. Expanding product range from GoFigure in early 2017 and the potential for global blockbuster products by spring 2017. | elrico | |
27/10/2016 14:54 | As a GP who is fairly heavily invested her I would not be surprised if this does not come under NHS prescribing at some point. Already we prescribe food supplements and are allowed to do so where a licensed alternative is not available. examples are vitamin d preparations and glucosamine. My own cholesterol at 7.5 puts me in the higher risk category which would benefit with the bigger reductions which have been observed. I am on a statin now and would love to come off it. My BP is also border line so another bonus. As other posters are aware cardiovascular disease is the biggest killer in the UK and diabetes is also massive ( 1/10 of patients where I work) and growing. This kind of disruptive product if it does do what it says on the tin could be exponential. I envisage higher doses in the pill format for prescription for higher risk patients, maybe pharma will do a combined version with a lower dose statin?? Then the addition to foods such as benecol. The opportunities are diverse. I think the multiple uses/products strategy is the correct one which would give the greatest income streams and revenue. Good luck to everyone holding Adnan | adnanwolf | |
27/10/2016 14:51 | Max says early 2017 for new product launches. | elrico | |
27/10/2016 14:50 | JH - agreed. I had assumed that one reason Fincap were brought in was because the previous broker had failed in taking out the II seller. However, the last 2 days it has been relentless and no sign of stopping. If they bought at 8p they could literally have millions to dump. | kipper1960 | |
27/10/2016 14:44 | john henry - "I find it quite astonishing that no OPTI brokers have managed to find an II willing to take the millions of shares that have been dumped this past 12 months." Why would they buy now when there's the possibility of a hugely discounted fund raise on the way? | ![]() michaelmouse | |
27/10/2016 14:35 | After all OHARA did say they had institutions that wanted to invest. He must have dreamt it | ![]() john henry | |
27/10/2016 14:35 | Hi 1bokke,Congratulatio | ![]() tightfist | |
27/10/2016 14:32 | I find it quite astonishing that no OPTI brokers have managed to find an II willing to take the millions of shares that have been dumped this past 12 months. | ![]() john henry | |
27/10/2016 14:17 | Thanks Someuwin, I have to say it has been easier than I thought it would be. | ![]() 1bokke | |
27/10/2016 14:10 | michaelmouse, I don't understand why you would spend so much time posting about a company you have no interest in? Do you have a vendetta against TW? Surely there are a lot more dubious companies on AIM with bigger shareholder interest if you are looking to promote your blog to a wider audience? I'd start with HNR. | mazzstar | |
27/10/2016 14:09 | Well done 1bokke - keep it up. They should be introducing some new flavours once development work is finished. | ![]() someuwin | |
27/10/2016 13:49 | Another months worth of shakes delivered. 9kg lost | ![]() 1bokke | |
27/10/2016 13:10 | I see a couple of posters are getting excited about the GoFigure bars and shakes. This market is absolutely saturated. Marketing spend will be enormous to get any foothold whatsoever. Oh sorry forgot that, "OptiBiotix's weight management division is now profitable with growing sales of GoFigure products and great consumer feedback and reorders." I look forward with interest to their full "divisional" breakdown. ;) | ![]() michaelmouse | |
27/10/2016 12:37 | Another great spot parob. It looks like they are pushing Go Figure very strongly through social media and promoting through personal fitness advisors | ![]() fozdad | |
27/10/2016 12:13 | Michaelmouse - Do you hold any shares in Opti? Or are you just waking up at 7:20am to post about how you think this is a pump and dump share...for the good of the people? I don't post here, I generally just come here to read what investors are saying - so wondering what your agenda is, if you don't mind me asking? Are you just trying to save us all? | loungeact | |
27/10/2016 12:10 | GoFigure Diet RetweetedHHH Health Retreats ?@HHHTeam Oct 21Loving our new energy bars and shakes from Max Tomlinson We'll definitely be using them on our next retreats! @GoFigureDiet | ![]() parob | |
27/10/2016 11:59 | The problem for you elrico is that many investors have been reading my blog for years, and they know I don't make up 'porky pies' or edit anything. I'm not right all the time, but right more than enough to have built up far more credibility than most. If you can quote any misinformation I have posted about Opti then please let me know. However, everything I have written and predicted has been quite prophetic to date. Huge fundraisings are coming for Opti, because mega-deals now seem more and more unlikely after yesterday's trading update. Winter is coming my friend.............. P.S. My nickname is "the rat-catcher" see the R4E thread!!! | ![]() michaelmouse | |
27/10/2016 11:39 | Just for you Elrico. Avanti was a poor speculation:- Trakm8 on the other hand has been a wonderful long term investment and will continue to be so for the foreseeable future:- All my trakm8 shares were purchased at prices between 10p-19p. That 2p dividend you mentioned represents a whopping double digit return on my original investment, not to mention the fantastic capital return. In fact, Trakm8 is arguably a far better and less risky investment now than when I was buying in 2011. Sorry for OT to all others. I don't give advice elrico, but if I held Opti shares then I'd sell up and buy into the profitable, cash generating, dividend paying, modestly priced growth company that is Trakm8. :) | ![]() michaelmouse | |
27/10/2016 11:26 | Yesterday's RNS was focussed purely on the cardiovascular opportunity. The email response make the multiple partners / opportunities even clearer... "The RNS highlights that we have a number of partners, including multinationals we are working with on this product opportunity. Some want consumer rights, other pharma rights, other manufacturing rights across a broad range of interlinked product opportunities." | ![]() someuwin | |
27/10/2016 11:24 | Seems the TW piece on being made an insider was R4E | ![]() scotty1 | |
27/10/2016 11:19 | someuwin - do we know they have multiple partners for the CV product range - or just one partner but multiple products. Just asking | kipper1960 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions